# Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck

> **NCT00084318** · PHASE2 · COMPLETED · sponsor: **Radiation Therapy Oncology Group** · enrollment: 238 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** cisplatin
- **DRUG:** docetaxel
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00084318
- **Lead sponsor:** Radiation Therapy Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2009-03
- **Final completion:** 2016-12
- **Target enrollment:** 238 (ACTUAL)
- **Last updated:** 2018-12-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00084318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00084318, "Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00084318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*